Bernstein Clinical Research Center

Running trials

• Active, not recruiting

  A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

  NCT06868212· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

  NCT06927999· Phase 2· ARS Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

  NCT06931405· Phase 2· Blueprint Medicines Corporation· Source

• Active, not recruiting

  A Study of Barzolvolimab in Patients With Atopic Dermatitis

  NCT06727552· Phase 2· Celldex Therapeutics· Source

• Active, not recruiting

  A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

  NCT06445023· Phase 3· Celldex Therapeutics· Source

• Active, not recruiting

  A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

  NCT06052267· Phase 3· Teva Branded Pharmaceutical Products R&D LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic spontaneous urticaria1 recruiting

Closed trials

• Completed

  Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)

  NCT07016412· Phase 2· Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA· Source

• Completed

  Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

  NCT06873516· Phase 2· Evommune, Inc.· Source

• Terminated

  Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

  NCT06524739· Phase 3· CSL Behring· Source

• Completed

  Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma

  NCT06102005· Phase 2· Sanofi· Source

• Terminated

  Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

  NCT06077773· Phase 2· Escient Pharmaceuticals, Inc· Source

• Completed

  A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  NCT05651711· Phase 3· Amgen· Source

• Completed

  Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma

  NCT05363670· Phase 2· ARS Pharmaceuticals, Inc.· Source

• Completed

  Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

  NCT04701983· Phase 3· Sanofi· Source

• Completed

  Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

  NCT04180488· Phase 3· Sanofi· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Chronic spontaneous urticaria8 works · 7 trials